Bullish
Eli Lilly's Jaypirca approved as first-line treatment for CLL/SLL patients
Eli Lilly's Jaypirca (pirtobrutinib) has received expanded FDA approval for first-line treatment of adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma without known 17p deletion. This approval is based on positive results from the BRUIN CLL-313 clinical trial, which demonstrated significant delay in disease progression compared to chemoimmunotherapy.
Key points
- FDA approves Jaypirca for first-line CLL/SLL treatment, enhancing Lilly's oncology portfolio.
- No significant market-moving news in the past 24 hours.
Sources
AI-generated from public news sources. Not financial advice.
